Navigation Links
Bell Ventures Launches Breakthrough Radical Defense Skin Care Ingredient
Date:12/8/2008

BOSTON, Dec. 8 /PRNewswire/ -- Bell Ventures LLC, a leader in innovative antioxidant solutions in food, nutrition, and skin care, announces the release of its new, high-performance natural ingredient, GlobalPAX(TM).

GlobalPAX(TM) is a proprietary extract made from the world's finest natural sources of proanthocyanidins (PACs), a powerful class of antioxidants. It is the first high-performance ingredient to standardize antioxidant capacity to Total ORAC, which analyzes antioxidant protection against 5 free radicals.

Bell Ventures also uses recognized markers of skin damage to demonstrate efficacy. GlobalPAX(TM) is standardized to collagenase and elastase inhibition, evidence that it helps defend against skin damage.

David Bell, President of Bell Ventures, says, "GlobalPAX(TM) is the result of our deep understanding of the science of antioxidants and our appreciation for their benefits to the skin. PACs are a very versatile antioxidant family, and we see this in the protection GlobalPAX(TM) delivers."

GlobalPAX(TM) provides powerful broad-spectrum defense against hydroxyl, peroxyl, peroxynitrite, singlet oxygen, and superoxide anion. Each of these radicals is implicated in skin damage.

The premium anti-aging skin care market is hungry for novel, high-performance naturals. The benefits of antioxidant protection provided by GlobalPAX(TM) make it ideal for differentiating next-generation products.

GlobalPAX(TM) has already received the attention of significant players in the industry. "We outperform a wide range of popular antioxidant ingredients, such as vitamin C, green tea extract, and green coffee cherry extract," Bell reports.

GlobalPAX(TM) can also be used to differentiate dietary supplements and the emerging category of inside-out skin care products and "beauty foods."

With standardized Total ORAC greater than 25,000 per gram, PACs, and
'/>"/>

SOURCE Bell Ventures LLC
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Starfish Ventures Closes Australias Largest Venture Capital Fund With $185 Million Tech Fund
2. West Michigans Newest Medical Device Company Receives Support from the West Michigan Science & Technology Initiative and EDF Ventures
3. BIO Ventures for Global Health Receives $7 Million Grant from Gates Foundation to Engage Biotechnology in the Fight Against Neglected Diseases of the Developing World
4. Medical Ventures Becomes Neovasc with Two Corporate Acquisitions and $8.3 Million Financing
5. MedAvante Closes $20 Million Financing by Goldman Sachs, Trevi Health Ventures
6. Oxford Finance Corporation and ATEL Ventures, Inc. Provide $7.5 Million Venture Loan to AxoGen, Inc.
7. SPO Medical Retains American Capital Ventures for Investor Relations Services
8. Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
9. The Bill & Melinda Gates Foundation, BIO, and Bio Ventures for Global Health Invite Proteome Systems CEO to Speak on TB Diagnostics Solutions At Partnering for Global Health Forum, Washington D.C.
10. Clarus Ventures Closes $660 Million Fund
11. 5AM Ventures Announces Expansion of Investment Team: Names Richard Ulevitch Venture Partner; Promotes Kevin Forrest and Andrew McMillan to Principal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)IRVINE, Calif., Dec. 4 BlueFire Ethanol Fuels, Inc. (OTC Bulletin Board: BFRE), a company focused on changing the world,s transportation fuel paradigm through the production of ethanol from non-food
(Date:12/3/2009)PHILADELPHIA, Dec. 3 Shire plc (LSE: SHP, Nasdaq: SHPGY ), the global specialty biopharmaceutical company, today announced a voluntary recall of five lots and voluntary market withdrawal of one lot
(Date:12/2/2009)COLUMBIA, Md., Dec. 2 Martek Biosciences Corporation (Nasdaq: MATK ) announced today that it intends to release the results of its fourth quarter and fiscal year 2009 on December 16, 2009, at approx
(Date:12/2/2009)NEW YORK, Dec. 2 Nearly 600 medical research executives, scientists, policy makers, and funders today convened to explore novel development approaches and innovative funding strategies at the inaugur
Breaking Biology Technology:BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 2BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 3BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 4Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 2Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 3Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 4Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 5Martek to Announce Fourth Quarter and Fiscal Year 2009 Results 2Medical Research Leaders Explore Novel Strategies to Expedite the Search for Cures 2
...s (CTI),(Nasdaq and MTA: CTIC) announced today tha...hareholders on February 27, 2009 in lieu of the Sp...o take place on February 6, 2009.,Shareholders of ...9, the,record date established by the Board of Dir...eting. Updated proxy materials, including an updat...
... (Nasdaq: NVAX ) a clinical-stage vaccine compan...d Chief Medical Officer, will be presenting at the...nce on January 26, 2009 at the Grand Hyatt in Wash...cus Session ,What benefits are single-use technolo...ns providing in practice, and will be speaking to ...
... with Acute Spinal Cord Injury , Geron Corpora...d and Drug,Administration (FDA) has granted cleara...) application for the clinical trial of GRNOPC1 in...ance enables Geron to move forward with,the world,...l-based therapy,in man. , Geron plans to initi...
Other Biology Technology:Novavax CMO to Present at Phacilitate Vaccine Forum Washington 2009 2Novavax CMO to Present at Phacilitate Vaccine Forum Washington 2009 3MultiVu Video Feed: Geron Receives FDA Clearance to Begin World's First Human Clinical Trial of Embryonic Stem Cell-Based Therapy 2
(Date:12/3/2009)The extinction of plant and animal species can be likened to emptying a museum of its collection, or dumping a cabinet full of potential medicines into the trash, or replacing every local cuisine with
(Date:12/3/2009)Grand Rapids, Mich. (Dec. 3, 2009) Van Andel Research Institute (VARI) researchers have determined precisely how the plant hormone abscisic acid (ABA) works at the molecular level to help plants re
(Date:12/3/2009)The UK leads the world when it comes to investment in energy efficient technologies research, but Engineering and Physical Sciences Research Council (EPSRC) Chief Executive Dave Delpy believes that mo
Breaking Biology News(10 mins):Species down, disease up 2Species down, disease up 3Species down, disease up 4VAI researchers find long awaited key to creating drought resistant crops 2VAI researchers find long awaited key to creating drought resistant crops 3Research is vital to a cleaner, greener, low carbon future 2By 2018 GlaxoSmithKlines Votrient Will Garner Sales of 24640 Million and Will Overtake Pfizers Sutent as the Renal Cell Carcinoma Market Leader 57010 1By 2018 GlaxoSmithKlines Votrient Will Garner Sales of 24640 Million and Will Overtake Pfizers Sutent as the Renal Cell Carcinoma Market Leader 57010 2Alexza Announces Preliminary Results from its AZ 104 28Staccato 28R 29 Loxapine 29 Phase 2b Trial in Patients with Migraine Headache 4993 1Alexza Announces Preliminary Results from its AZ 104 28Staccato 28R 29 Loxapine 29 Phase 2b Trial in Patients with Migraine Headache 4993 2Alexza Announces Preliminary Results from its AZ 104 28Staccato 28R 29 Loxapine 29 Phase 2b Trial in Patients with Migraine Headache 4993 3Alexza Announces Preliminary Results from its AZ 104 28Staccato 28R 29 Loxapine 29 Phase 2b Trial in Patients with Migraine Headache 4993 4Alexza Announces Preliminary Results from its AZ 104 28Staccato 28R 29 Loxapine 29 Phase 2b Trial in Patients with Migraine Headache 4993 5Heart Failure Society of America 13th Annual Scientific Meeting to Focus on a Bench To Bedside Approach 4989 1Heart Failure Society of America 13th Annual Scientific Meeting to Focus on a Bench To Bedside Approach 4989 2Heart Failure Society of America 13th Annual Scientific Meeting to Focus on a Bench To Bedside Approach 4989 3
...e fast disappearing from restaurant menus as stock... While the reasons for the eel decline remain as m...y a NOAA scientist and colleagues in Japan and the...nditions may be a primary factor in declining repr...ects of spawning and early life history of this sp...
...t of champions? That would be a soy protein-packed...ements for three different FDA health claims and l...at again until lunch. , University of Illinois sc...st such a cereal, one thats passed the taste test ...asons to eat soy--and even more reasons to consume...
...pleased to announce the launch of the Internationa...llows on the heels of the Panda Genome workshop he...Hongmei Zhu, a scientist from BGI-Shenzhen, stated...sequencing and assembling of the draft sequence wi...ved animal all over the world and is considered a ...
Other Biology News:Changes in ocean conditions in Sargasso Sea potential cause for decline in eel fishery 2Changes in ocean conditions in Sargasso Sea potential cause for decline in eel fishery 3U of I researcher develops power-packed soy breakfast cereal 2Giant panda genome to be sequenced 2Giant panda genome to be sequenced 3
5-bromouridine 5'-triphosphate (BrUTP) *10 mM in TE buffer* from Molecular Probes (Invitrogen)
ER-beta Fluorescence polarization Assay Kit from Invitrogen
GIBCO MEM Non-Essential Amino Acids Solution 10 mM (100X), liquid from Invitrogen
...rains are K-12 derivatives that have mutations in ...one reductase (gor) genes, which greatly enhances ... have shown that expression in Origami(DE3) yielde... even though overall expression levels were simila...
Biology Products: